Kazutoshi Fujita

Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study

ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose) polymerase inhibitors (PARPi). However, real‐world i...

Impact of baseline renal function on the clinical outcomes and safety of adjuvant nivolumab in high-risk urothelial carcinoma: a multicenter retrospective real-world study

Abstract Background Adjuvant nivolumab prolongs disease-free survival (DFS) in patients with urothelial carcinoma (UC) after radical surgery; however, evidence in those with reduced baseline renal function is limited. We investigated the impact of baseline creatinine clearance (C...

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer

BACKGROUND: Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone-sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite sec...

[ 18 F ] PSMA ‐1007 PET –Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer

ABSTRACT Objectives Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is a sensitive imaging modality for detecting recurrent prostate cancer following definitive local therapy. However, evidence on 18 F‐labeled PSMA tracers in Japanese patients with bioc...